Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Putelimab and Vibostolimab as Second-Line Therapy in Patients With Advanced Anal Squamous Cell Carcinoma

NCT07934745 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07934745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Putelimab and Vibostolimab as Second-Line Therapy in Patients With Advanced Anal Squamous Cell Carcinoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2028
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer

Arms

As registered; 1 arm.

  • treatment Experimentalputelimab combined with vibostolimab

    Radiotherapy is delivered to recurrent or metastatic lesions. Thereafter, the PD-1 inhibitor putelimab in combination with the EGFR-targeted ADC vibostolimab is administered once every 3 weeks until disease progression or intolerable toxicity.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Objective Response Rate (ORR) From enrolment until first documented disease progression, death, subsequent anti-cancer therapy, or loss to follow-up,assessed up to 24 months. Responses require confirmation ≥4 weeks after first documentation.

    the proportion of participants achieving a Complete Response (CR) or Partial Response (PR) among all enrolled participants.

Lead sponsor's other trials

Fudan University, most recent start first.

Similar trials

Same condition (Anus Neoplasms) and phase, most recent start first.